[Dyspnoea due to ticagrelor after recent myocardial infarction]

Ned Tijdschr Geneeskd. 2022 Nov 9:166:D6859.
[Article in Dutch]

Abstract

Background: Ticagrelor is a frequently prescribed platelet aggregation inhibitor used in patients with acute coronary syndrome. A rare side effect is severe dyspnoea.

Case description: A 76 year old woman experiences severe shortness of breath three weeks after percutaneous coronary intervention because of acute myocardial infarction. Physical examination and additional investigation showed no pulmonary or cardiac explanation for her complaints. Shortly after cessation of ticagrelor, her complaints disappeared.

Conclusion: Ticagrelor-related severe dyspnoea in post-myocardial infarction patients is a diagnosis by exclusion of other reasonable causes of dyspnoea. Unfamiliarity with this side effect can lead to excess diagnostics and unnecessary referrals.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Acute Coronary Syndrome* / diagnosis
  • Aged
  • Dyspnea / etiology
  • Female
  • Humans
  • Myocardial Infarction* / diagnosis
  • Myocardial Infarction* / drug therapy
  • Percutaneous Coronary Intervention* / adverse effects
  • Platelet Aggregation Inhibitors / adverse effects
  • Ticagrelor / adverse effects
  • Treatment Outcome

Substances

  • Ticagrelor
  • Platelet Aggregation Inhibitors